Dr. Susanibar on Important Considerations When Treating Multiple Myeloma
Sandra P. Susanibar-Adaniya, MD, discusses important considerations when treating patients with multiple myeloma.
Dr. Susanibar-Adaniya on the Impact of the MAIA and GRIFFIN Trials in Multiple Myeloma Treatment
Sandra P. Susanibar-Adaniya, MD, discusses 2 key trials in multiple myeloma that improved the treatment landscape for transplant-eligible and ineligible patients.
Dr. Susanibar-Adaniya on the Standard of Care for Patients With Newly Diagnosed Multiple Myeloma
Sandra P. Susanibar-Adaniya, MD, discusses the current standard of care for patients with newly diagnosed multiple myeloma.
Dr. Susanibar-Adaniya on the Evolution of Combination Therapies in Multiple Myeloma
Sandra P. Susanibar-Adaniya, MD, discusses how advancements in triplet therapy have shifted the treatment paradigm for patients with newly diagnosed, transplant-ineligible multiple myeloma.
Continued ADC Development in NSCLC Necessitates Improved Knowledge of Mechanisms and Biomarker Optimization
Neoadjuvant vs Perioperative Immune Checkpoint Blockade in Resectable NSCLC: How Do We Choose?
EGFR TKI–Based Combinations May Revolutionize Frontline EGFR+ NSCLC Management
Dr Olazagasti on a Case-Based Discussion of ALK-Mutated NSCLC Treatment
2 Commerce Drive Cranbury, NJ 08512